As with other sulfonylurea-class hypoglycemics, many stable non-insulin-dependent diabetic patients receiving insulin may be safely placed on GLUCOTROL. When transferring patients from insulin to GLUCOTROL, the following general guidelines should be considered:

During the insulin withdrawal period, the patient should test urine samples for sugar and ketone bodies at least three times daily. Patients should be instructed to contact the prescriber immediately if these tests are abnormal. In some cases, especially when patient has been receiving greater than 40 units of insulin daily, it may be advisable to consider hospitalization during the transition period.

As with other sulfonylurea-class hypoglycemics, no transition period is necessary when transferring patients to GLUCOTROL. Patients should be observed carefully (1–2 weeks) for hypoglycemia when being transferred from longer half-life sulfonylureas (e.g., chlorpropamide) to GLUCOTROL due to potential overlapping of drug effect.

GLUCOTROL tablets are white, dye-free, scored, diamond-shaped, and imprinted as follows:

5 mg–Pfizer 411; 10 mg–Pfizer 412.

5 mg Bottles: 100's (NDC 0049-4110-66)
10 mg Bottles: 100's (NDC 0049-4120-66)

Store below 86°F (30°C).

Rx only

LAB-0114-6.0August 2010

NDC 0049-4110-66

100 Tablets

Glucotrol (glipizide)

5 mg

Pfizer Roerig Division of Pfizer Inc, NY, NY 10017

NDC 0049-4120-66

100 Tablets

Glucotrol (glipizide)

10 mg

Pfizer Roerig Division of Pfizer Inc, NY, NY 10017

Manufacturer
Roerig

Active Ingredients
Source
U.S. National Library of Medicine
DailyMed
Last Updated: 2nd of March 2011